Retinopathy of prematurity is a common disorder among extremely low-birthweight preterm infants and may cause total vision loss in as many as 2% to 4% of those weighing less than 2 pounds at birth. Regular examinations begun in the neonatal intensive care unit permit early detection and treatment of progressive ROP and allow a reduction in visual impairment. Infants whose ROP has regressed should continue to receive regular ophthalmologic follow-up for the detection and treatment of myopia and strabismus and, if they have cicatricial sequelae, late retinal detachments as teens or adults. Early intervention and special education programs are important for the children whose vision loss is significant.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1542/pir.16-2-50 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of bleb-like retinal detachment in aggressive retinopathy of prematurity.
BMJ Case Rep
January 2025
ABRI, LV Prasad Eye Institute, GMRV Campus, Visakhapatnam, Andhra Pradesh, India
Bleb-like retinal detachment (BLRD) in posterior zone 1 retinopathy of prematurity (ROP) presents a significant therapeutic challenge and is associated with a guarded visual prognosis. We present a case of a female infant born preterm with a birth weight of 1100 g. Examination revealed bilateral stage 4 aggressive ROP in posterior zone 1 with BLRD.
View Article and Find Full Text PDFA meta-analysis of intravitreal ranibizumab versus laser photocoagulation for the treatment of retinopathy of prematurity.
Ophthalmol Retina
January 2025
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada; John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Canada. Electronic address:
Purpose: Laser photocoagulation (LPC) has been a traditional treatment for retinopathy of prematurity (ROP). However, intravitreal anti-VEGF agents such as bevacizumab and ranibizumab (IVR) have also been increasingly used. This meta-analysis aims to rigorously compare IVR to LPC in the treatment of ROP.
View Article and Find Full Text PDFThe U.S.A. eligible retinopathy of prematurity screening population 2003-2022: WONDER-ROP Study.
Early Hum Dev
January 2025
Pr3vent, Inc, Palo Alto, CA, United States of America; Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address:
Purpose: To delineate the trends of the United States population eligible for retinopathy of prematurity (ROP) screening as defined by the Joint Statement Screening Guidelines of the American Academies of Pediatrics and Ophthalmology from the Centers for Disease Control using the Wide-ranging Online Data for Epidemiologic Research (WONDER) Database.
Design: National, retrospective study.
Subjects: Infants with ROP in the United States between 2003 and 2022.
Risk factors for noninvasive ventilation failure in preterm infants at less than 30 weeks of gestation with respiratory distress syndrome.
J Trop Pediatr
December 2024
Division of Neonatology, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, 06800, Turkey.
This study aimed to identify risk factors for noninvasive ventilation (NIV) failure in <30 weeks' gestation preterm neonates and compare morbidity in patients with and without NIV failure. This study included preterm neonates <30 weeks' gestation who received NIV support for respiratory distress syndrome (RDS). Demographic and clinical characteristics were compared between infants with and without NIV failure within the first 72 hours after birth.
View Article and Find Full Text PDFConstruction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study.
Front Pediatr
January 2025
Department of Neonatology, The First Affiliated Hospital of Zheng Zhou University, Zhengzhou, China.
Objective: To explore the risk factors for the reactivate of retinopathy of prematurity (ROP) after intravitreal injection of anti-vascular endothelial growth factor (VEGF) and to construct a nomogram model to predict the risk of ROP reactivate.
Methods: A retrospective analysis was conducted on 185 ROP children who underwent anti-VEGF treatment at the First Affiliated Hospital of Zhengzhou University from January 2017 to October 2023. They were randomly divided into a training set (129 cases) and a validation set (56 cases) at a ratio of 7:3.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!